Dr. Paul Burton to Join Moderna as Chief Medical Officer
June 14 2021 - 8:10AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that Paul Burton, M.D., Ph.D., F.A.C.C, M.R.C.S will join the
Company as Chief Medical Officer, effective July 6, 2021. He will
serve on Moderna’s Executive Committee and report to Chief
Executive Officer Stéphane Bancel.
“Paul’s extensive medical experience in the global
pharmaceutical and biotech industry will be important to Moderna as
we expand internationally and continue our journey as a commercial
company,” said Stéphane Bancel, Chief Executive Officer of Moderna.
“As we work to deliver on the promise of mRNA science to create a
new generation of transformative medicines for patients, Paul’s
expertise across multiple therapeutic areas and his proven track
record leveraging data science and digital technologies to
reimagine medical engagement will be invaluable. I look forward to
working with Paul and re-inventing how medical affairs should be
built and run in a digital world.”
Dr. Burton joins Moderna after spending sixteen years with
Johnson & Johnson (NYSE: JNJ). Since March 2020, he served as
Chief Global Medical Affairs Officer of Janssen Pharmaceuticals
where he was responsible for Janssen’s worldwide medical affairs
strategy and execution. Previously, he served as Janssen’s Vice
President and Head, Cardiovascular and Metabolic (CVM) Medical
Affairs. Dr. Burton also led the Johnson & Johnson
collaboration with APPLE for the digital HEARTLINE™ study, and
previously led clinical operations for all therapeutic areas across
the Americas.
“Moderna’s transformative platform has the potential to improve
the lives of so many people around the world,” said Dr. Burton. “I
am honored to take on the role of Chief Medical Officer at
Moderna.”
Dr. Burton has an M.D. from the University of London, is board
certified in surgery and is a Member of the Royal College of
Surgeons with specialist training in cardiothoracic surgery. He
holds a Ph.D. in cardiovascular molecular and cellular biology from
Imperial College in London and is a Fellow of the American College
of Cardiology. He has published extensively in peer reviewed
journals.
Earlier in 2021, the Company announced that Moderna’s Chief
Medical Officer Tal Zaks, M.D., Ph.D., will be leaving the Company
after six years of service.
“As Paul prepares to join us, I would like to thank Tal once
again for his impact over the last six years. Tal’s guidance and
contributions were important in helping Moderna move from a
preclinical company to where we are today. Through his leadership
in Moderna’s response to the COVID-19 pandemic, Tal’s contribution
extends beyond Moderna to all of society. I have enjoyed having him
as my partner and wish him all the best,” said Stéphane Bancel.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and autoimmune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 14 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s hiring Dr.
Paul Burton as Chief Medical Officer and the Company’s efforts to
apply digital technologies to mRNA-based medicine. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC’s website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna’s current expectations and speak only as of the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005414/en/
Moderna Contacts Media: Colleen Hussey Director,
Corporate Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024